The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Lilly’s SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE:LLY) SURPASS-2 clinical trial, which were
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
45 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
36 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 145 companies set new 52-week highs.
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $300
Cantor Fitzgerald analyst Louise Chen maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $245 to $300.
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
Lilly’s Donanemab Receives U.S. FDA’s Breakthrough Therapy Designation For Treatment Of Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE:LLY) investigational antibody therapy for Alzheimer's disease (AD). The